帕金森病左旋多巴剂峰异动症的治疗  

Medicinal Treatment of L-dopa Peak-dose Dyskinesias in Parkinson's Disease and Related Literature Review

作　　者：白雪[1] 蒋雨平[2] BAI Xue JIANG Yu-ping(Department of Neurology, Chifeng Municipal Hospital, Chifeng 024000, China Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China)

机构地区：[1]赤峰市医院神经内科,024000 [2]复旦大学附属华山医院神经内科,200040

出　　处：《中国临床神经科学》2017年第3期301-305,共5页Chinese Journal of Clinical Neurosciences

摘　　要：帕金森病(PD)是一种神经系统退行性疾病,左旋多巴仍是治疗PD的金标准用药,但是随着疾病的发展,长期服用左旋多巴会出现左旋多巴诱发异动症(LID),LID是常见的运动并发症。文中主要讨论LID的临床表现及治疗问题。PD is a neurodegenerative disease. L-dopa is still the gold standard for the treatment of Parkinson＇s disease （PD）. L-dopa-induced dyskinesia （LID） is one of the main types of drug-induced dyskinesia, occurring in patients with PD who have been treated with levodopa for long time. A variety of emerging drugs currently in development promise to providea a better control of LIDs in near future. The clinical manifestations and pharmacology treatment of LID were discussed.

关 键 词：帕金森病 异动症 左旋多巴 

分 类 号：R512.3[医药卫生—内科学]